© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Endocrinology
Help Shape the Future of Denosumab Treatment
As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.
Take the survey now and make your voice heard
Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.
At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.
Your daily dose of the clinical news you may have missed.
This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.
Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
People with obesity may shun basic primary care for fear of shaming, lectures, inhospitable equipment, and simple lack of respect from clinicians, authors found.
The combination of the Dexcom Stelo glucose biosensor with an AI platform provides real-time data on how food, exercise, stress, and sleep affect the body.
GLP-1 use was associated with lower overall cancer risk, with the strongest associations observed for endometrial and ovarian cancers and meningioma.
Your daily dose of the clinical news you may have missed.
The FDA's ODD award is based on the positive findings from the phase 2 TouCAHn trial, which also support Crinetics' robust phase 3 pivotal clinical trial program for the novel agent.